These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Montero JC; Seoane S; Ocaña A; Pandiella A Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084 [TBL] [Abstract][Full Text] [Related]
63. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Agarwal E; Brattain MG; Chowdhury S Cell Signal; 2013 Aug; 25(8):1711-9. PubMed ID: 23603750 [TBL] [Abstract][Full Text] [Related]
64. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765 [TBL] [Abstract][Full Text] [Related]
65. Exploiting novel molecular targets in gastrointestinal cancers. Ma WW; Hidalgo M World J Gastroenterol; 2007 Nov; 13(44):5845-56. PubMed ID: 17990350 [TBL] [Abstract][Full Text] [Related]
66. Emerging therapeutics for targeting Akt in cancer. Gdowski A; Panchoo M; Treuren TV; Basu A Front Biosci (Landmark Ed); 2016 Jan; 21(4):757-68. PubMed ID: 26709804 [TBL] [Abstract][Full Text] [Related]
67. Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer. Mita AC; Mita MM; Rowinsky EK Clin Colorectal Cancer; 2004 Jul; 4(2):107-23. PubMed ID: 15285818 [TBL] [Abstract][Full Text] [Related]
68. MET pathway as a therapeutic target. Kim ES; Salgia R J Thorac Oncol; 2009 Apr; 4(4):444-7. PubMed ID: 19333071 [TBL] [Abstract][Full Text] [Related]
69. The emergence of TNIK as a therapeutic target for colorectal cancer. Masuda M; Yamada T Expert Opin Ther Targets; 2017 Apr; 21(4):353-355. PubMed ID: 28281900 [No Abstract] [Full Text] [Related]
70. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691 [TBL] [Abstract][Full Text] [Related]
71. Starving cancer cells. Habeck M Drug Discov Today; 2002 Jun; 7(12):635-6. PubMed ID: 12110233 [No Abstract] [Full Text] [Related]
72. Relevance of EGFR expression in colorectal cancer. Alliot C Ann Oncol; 2005 Sep; 16(9):1557-8; author reply 1558-9. PubMed ID: 15870082 [No Abstract] [Full Text] [Related]
73. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179 [TBL] [Abstract][Full Text] [Related]
74. Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells. Aleksic T; Feller SM Cell Commun Signal; 2008 Oct; 6():8. PubMed ID: 18950493 [TBL] [Abstract][Full Text] [Related]
80. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]